{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:53:06Z","timestamp":1768009986045,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41375-025-02805-1","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T11:00:53Z","timestamp":1763377253000},"page":"247-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to the commentary by Xu et al. on the PV-AIM study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-7004","authenticated-orcid":false,"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the PV-AIM investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Zaiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kisro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"G\u00fcckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Gro\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike W.","family":"Zuurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armita","family":"Afsharinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2805_CR1","doi-asserted-by":"publisher","unstructured":"Xu F, Li Z, Fu H, Ma J. Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02807-z.","DOI":"10.1038\/s41375-025-02807-z"},{"key":"2805_CR2","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/s41375-025-02623-5","volume":"39","author":"FH Heidel","year":"2025","unstructured":"Heidel FH, De Stefano V, Zaiss M, Kisro J, Guckel E, Grosser S, et al. Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM). Leukemia. 2025;39:1692\u2013701.","journal-title":"Leukemia"},{"key":"2805_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3324\/haematol.2023.283987","volume":"110","author":"VY Ling","year":"2025","unstructured":"Ling VY, Heidel FH, Bywater MJ. Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica. 2025;110:863\u201376.","journal-title":"Haematologica"},{"key":"2805_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner F, Pahl HL, Zeiser R, Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 2025;39:1011\u201330.","journal-title":"Leukemia"},{"key":"2805_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2805_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/biomedicines11071925","volume":"11","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Krecak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, et al. Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project. Biomedicines. 2023;11:1925.","journal-title":"Biomedicines"},{"key":"2805_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41375-025-02524-7","volume":"39","author":"K Manz","year":"2025","unstructured":"Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, et al. Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Leukemia. 2025;39:864\u201375.","journal-title":"Leukemia"},{"key":"2805_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","volume":"39","author":"F Palandri","year":"2025","unstructured":"Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, et al. Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea. Leukemia. 2025;39:1928\u201336.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02805-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:04:01Z","timestamp":1767985441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02805-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02805-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FHH served as an advisor for Novartis, CTI, BMS, Janssen, Abbvie, GSK, Merck, and AOP and received research funding from Novartis, Celgene\/BMS and CTI. J-JK reported receiving consulting fees from AbbVie, BMS, and Novartis; payment or honoraria for lectures, presentations, or educational events from AOP, BMS\/Celgene, and Novartis; participated on a DSM Board or Advisory Board for Incyte. M.G. has provided consultancy services for, and received honoraria from AOP, Novartis, BMS, AbbVie, Roche, Janssen, Gilead Sciences, AstraZeneca, Sierra, Eli Lilly and GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}